- St Lucia became 100th country to receive vaccines.
- 38 mln doses delivered in six weeks.
- Despite supply issues, 2 billion doses to be provided in 2021.
GENEVA: Six weeks after the COVAX vaccine facility began to roll out vaccine supplies, the scheme on Thursday said it had delivered nearly 38.4 million doses of COVID-19 jabs to 102 countries and economies across six continents.
The programme offers a lifeline to low-income countries in particular, allowing them in the first instance to inoculate health workers and others at high risk, even if their governments have not managed to secure vaccines from the manufacturers.
But there have been some delays, the GAVI vaccine alliance and World Health Organization said in a statement.
Reduced availability of delayed some deliveries in March and April, and much of the output of the Serum Institute of India, which makes the AstraZeneca vaccine, is being kept in India, where daily infections surpassed 100,000 for the first time on Monday.
The Caribbean island of St. Lucia became the 100th country to receive vaccines through COVAX. Iran, also battling a record rate of infection, is another recent recipient.
The 102 countries reached so far include 61 benefiting from a mechanism essentially financed by donors.
WHO Director-General Tedros Adhanom Ghebreyesus on Monday called it a “travesty” that some countries still did not have enough vaccines to begin inoculating health workers and the most vulnerable.
GAVI said last month that it planned to deliver 237 million doses of the AstraZeneca vaccine — which has been produced at cost for a few dollars a dose, and does not require the advanced refrigeration of some other coronavirus vaccines — to 142 countries by the end of May.
“COVAX may be on track to deliver to all participating economies in the first half of the year, yet we still face a daunting challenge as we seek to end the acute stage of the pandemic,” GAVI chief executive Seth Berkley said in the statement.
Nonetheless, COVAX still expects to deliver at least 2 billion doses this year 2021, and to diversify the offering beyond the AstraZeneca/Oxford and Pfizer/BioNTech shots it is currently supplying.